TY - JOUR
T1 - Comparative performance of diagnosis-based and prescription-based comorbidity scores to predict health-related quality of life
AU - Mehta, Hemalkumar B.
AU - Sura, Sneha D.
AU - Sharma, Manvi
AU - Johnson, Michael L.
AU - Riall, Taylor S.
N1 - Publisher Copyright:
© 2013 Wolters Kluwer Health, Inc.
PY - 2016
Y1 - 2016
N2 - Objectives: To compare the performance of the health-related quality of life-comorbidity index (HRQoL-CI) with the diagnosisbased Charlson, Elixhauser, and combined comorbidity scores and the prescription-based chronic disease score (CDS) in predicting HRQoL in Agency of Healthcare Research and Quality priority conditions (asthma, breast cancer, diabetes, and heart failure). Methods: The Medical Expenditure Panel Survey (2005 and 2007-2011) data was used for this retrospective study. Four diseasespecific cohorts were developed that included adult patients (age 18 y and above) with the particular disease condition. The outcome HRQoL [physical component score (PCS) and mental component score (MCS)] was measured using the Short Form Health Survey, Version 2 (SF-12v2). Multiple linear regression analyses were conducted with the PCS and MCS as dependent variables. Comorbidity scores were compared using adjusted R2. Results: Of 140,046 adult participants, the study cohort included 7436 asthma (5.3%), 1054 breast cancer (0.8%), 13,829 diabetes (9.9%), and 937 heart failure (0.7%) patients. Among individual scores, HRQoL-CI was best at predicting PCS and MCS. Adding prescription-based comorbidity scores to HRQoL-CI in the same model improved prediction of PCS and MCS. HRQoL-CI+CDS performed the best in predicting PCS (adjusted R2): asthma (43.7%), breast cancer (31.7%), diabetes (32.7%), and heart failure (20.0%). HRQoL-CI+CDS and Elixhauser+CDS had superior and comparable performance in predicting MCS (adjusted R2): asthma (HRQoL-CI+CDS = 20.1%; Elixhauser+CDS = 19.6%), breast cancer (HRQoL-CI+CDS = 12.9%; Elixhauser+CDS = 14.1%), diabetes (HRQoL-CI+CDS = 17.7%; Elixhauser+CDS = 17.7%), and heart failure (HRQoL-CI+CDS = 18.1%; Elixhauser+CDS = 17.7%). Conclusions: HRQoL-CI performed best in predicting HRQoL. Combining prescription-based scores to diagnosis-based scores improved the prediction of HRQoL.
AB - Objectives: To compare the performance of the health-related quality of life-comorbidity index (HRQoL-CI) with the diagnosisbased Charlson, Elixhauser, and combined comorbidity scores and the prescription-based chronic disease score (CDS) in predicting HRQoL in Agency of Healthcare Research and Quality priority conditions (asthma, breast cancer, diabetes, and heart failure). Methods: The Medical Expenditure Panel Survey (2005 and 2007-2011) data was used for this retrospective study. Four diseasespecific cohorts were developed that included adult patients (age 18 y and above) with the particular disease condition. The outcome HRQoL [physical component score (PCS) and mental component score (MCS)] was measured using the Short Form Health Survey, Version 2 (SF-12v2). Multiple linear regression analyses were conducted with the PCS and MCS as dependent variables. Comorbidity scores were compared using adjusted R2. Results: Of 140,046 adult participants, the study cohort included 7436 asthma (5.3%), 1054 breast cancer (0.8%), 13,829 diabetes (9.9%), and 937 heart failure (0.7%) patients. Among individual scores, HRQoL-CI was best at predicting PCS and MCS. Adding prescription-based comorbidity scores to HRQoL-CI in the same model improved prediction of PCS and MCS. HRQoL-CI+CDS performed the best in predicting PCS (adjusted R2): asthma (43.7%), breast cancer (31.7%), diabetes (32.7%), and heart failure (20.0%). HRQoL-CI+CDS and Elixhauser+CDS had superior and comparable performance in predicting MCS (adjusted R2): asthma (HRQoL-CI+CDS = 20.1%; Elixhauser+CDS = 19.6%), breast cancer (HRQoL-CI+CDS = 12.9%; Elixhauser+CDS = 14.1%), diabetes (HRQoL-CI+CDS = 17.7%; Elixhauser+CDS = 17.7%), and heart failure (HRQoL-CI+CDS = 18.1%; Elixhauser+CDS = 17.7%). Conclusions: HRQoL-CI performed best in predicting HRQoL. Combining prescription-based scores to diagnosis-based scores improved the prediction of HRQoL.
KW - Charlson comorbidity score
KW - Chronic disease score
KW - Comorbidity scores
KW - Elixhauser comorbidity score
KW - Health-related quality of life (HRQoL)
KW - Risk adjustment
UR - http://www.scopus.com/inward/record.url?scp=84959208772&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959208772&partnerID=8YFLogxK
U2 - 10.1097/MLR.0000000000000517
DO - 10.1097/MLR.0000000000000517
M3 - Article
C2 - 26918403
AN - SCOPUS:84959208772
SN - 0025-7079
VL - 54
SP - 519
EP - 527
JO - Medical care
JF - Medical care
IS - 5
ER -